Effectiveness of Higher Aspirin Dosing for Prevention of Preeclampsia in High Risk Obese Gravida
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 220 participants.
Also called NCT03961360
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 220 participants
- Registry
-
NCT03961360
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT03961360. Randomized; no masking; primary purpose treatment. Start 2019-05-06 (actual); primary completion 2023-04-10 (actual). Results posted on 2024-05-08.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effectiveness of Higher Aspirin Dosing for Prevention of Preeclampsia in High Risk Obese Gravida
- Acronym
- ASPREO
- Condition
- Pre-Eclampsia
- Condition
- Hypertension in Pregnancy
- Condition
- Obesity
- Intervention (Drug)
- Aspirin 81 mg
- Intervention (Drug)
- Aspirin 162 mg
- Lead sponsor
- The University of Texas Health Science Center, Houston
Record details
- Record id
cardio:ct-nct03961360- Content hash
92e0b7c5db16e0e14da2f51835acea417684faf945d2804ea8d4227f33ba3c20